1. Home
  2. GDDY vs ABVX Comparison

GDDY vs ABVX Comparison

Compare GDDY & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoDaddy Inc.

GDDY

GoDaddy Inc.

HOLD

Current Price

$86.82

Market Cap

11.7B

Sector

Technology

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$121.36

Market Cap

9.7B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDDY
ABVX
Founded
1997
2013
Country
United States
France
Employees
N/A
67
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
11.7B
9.7B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
GDDY
ABVX
Price
$86.82
$121.36
Analyst Decision
Buy
Buy
Analyst Count
16
13
Target Price
$136.44
$131.31
AVG Volume (30 Days)
1.9M
813.2K
Earning Date
04-30-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.60
N/A
Revenue
N/A
N/A
Revenue This Year
$7.94
$52.14
Revenue Next Year
$6.10
$4,132.27
P/E Ratio
$54.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$73.06
$5.59
52 Week High
$190.50
$148.83

Technical Indicators

Market Signals
Indicator
GDDY
ABVX
Relative Strength Index (RSI) 51.00 53.65
Support Level $80.41 $107.29
Resistance Level $92.66 $129.84
Average True Range (ATR) 4.00 4.84
MACD 0.26 0.83
Stochastic Oscillator 35.50 66.52

Price Performance

Historical Comparison
GDDY
ABVX

About GDDY GoDaddy Inc.

GoDaddy Inc provides digital solutions and services for entrepreneurs, small businesses, individuals, organizations, developers, designers, and domain investors. It offers tools intended to support business creation and management through an integrated service platform. The company operates through two segments: Applications and Commerce (A&C) and Core Platform (Core). The majority of the company's revenue is derived from the Core Platform segment, which consists of sales of domain registrations and renewals, aftermarket domain sales, website hosting products and website security products. Geographically, it generates the maximum revenue from the United States.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: